financetom
Business
financetom
/
Business
/
Consumer Staple Stocks Poised for Outperformance as Fed Rate Cuts Loom, Oppenheimer Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Consumer Staple Stocks Poised for Outperformance as Fed Rate Cuts Loom, Oppenheimer Says
Sep 11, 2024 11:35 AM

02:07 PM EDT, 09/11/2024 (MT Newswires) -- Consumer staple stocks likely face "a more favorable" setup for outperformance amid expectations for the Federal Reserve to start easing its monetary policy soon, Oppenheimer said Wednesday.

Last month, Fed Chair Jerome Powell said the "time has come" to start cutting interest rates, though the timing and extent of policy easing will depend on incoming data. The central bank's Federal Open Market Committee increased its benchmark lending rate by 525 basis points from March 2022 through July 2023 in a bid to combat inflation, but has since held monetary policy steady.

"As we look at our consumer staples playbook, the recent change in the interest-rate backdrop coupled with valuations near trough levels create a more favorable setup for outperformance from here," Oppenheimer analysts Rupesh Parikh and Erica Eiler said in a note to clients.

The brokerage continues to see Church & Dwight ( CHD ) , Freshpet ( FRPT ) and Prestige Consumer Healthcare ( PBH ) as its top sector picks. The analysts said that e.l.f. Beauty (ELF), Hormel Foods ( HRL ) and Utz Brands ( UTZ ) "remain on our radar."

Past data suggest that consumer staple stocks have outperformed the broader market during periods of policy easing, with outperformance relative to the S&P 500 in four of the last five periods of rate cuts, Oppenheimer said.

The group has outperformed in six of the last seven periods of decreases in US Treasury yields, with "nearly every" beverage, food, and household and personal products company name in the brokerage's study outperforming on average, Parikh and Eiler said.

On Wednesday, government data showed consumer inflation in the US rose as expected last month sequentially, while the annual metric logged the smallest increase since February 2021.

The odds of a 25-basis-point interest-rate cut next week jumped to 87% Wednesday from 66% Tuesday, while the probability of a more aggressive 50-basis-point reduction fell to 13% from 34%, according to the CME FedWatch tool.

"Historically, the consumer staples group has generally outperformed in the six months following the initial fed funds rate cut, which suggests to us a favorable outlook for the group, assuming Fed fund rate decreases materialize," Parikh and Eiler wrote.

Price: 103.31, Change: -2.63, Percent Change: -2.49

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Beam Therapeutics Swings to Q4 Loss as Revenue Falls
Beam Therapeutics Swings to Q4 Loss as Revenue Falls
Feb 25, 2025
08:08 AM EST, 02/25/2025 (MT Newswires) -- Beam Therapeutics ( BEAM ) reported a Q4 loss Tuesday of $1.09 per diluted share, swinging from a profit of $1.73 a year earlier. Analysts polled by FactSet expected a loss of $1.23. License and collaboration revenue for the quarter ended Dec. 31 was $30.1 million, down from $316.2 million a year earlier....
Trump Says U.S. Trade Tariffs Against Canada, Mexico Are Moving Ahead, Notes ING
Trump Says U.S. Trade Tariffs Against Canada, Mexico Are Moving Ahead, Notes ING
Feb 25, 2025
08:10 AM EST, 02/25/2025 (MT Newswires) -- President Donald Trump at the start of the week claimed that United States tariffs on Canada and Mexico are moving ahead, noted ING. The 25% U.S. duties were delayed by one month at the start of February and next Monday is the new deadline to avert a USMCA trade war, said the bank....
Kiniksa Pharmaceuticals Swings to Q4 Loss, Revenue Increases
Kiniksa Pharmaceuticals Swings to Q4 Loss, Revenue Increases
Feb 25, 2025
08:07 AM EST, 02/25/2025 (MT Newswires) -- Kiniksa Pharmaceuticals International ( KNSA ) reported a Q4 loss Tuesday of $0.12 per diluted share, swinging from earnings of $0.35 per share a year earlier. Analysts polled by FactSet expected earnings of $0.02. Revenue for the quarter ended Dec. 31 was $122.5 million, up from $83.4 million a year earlier. Analysts surveyed...
Delek US Q4 Adjusted Net Loss Widens, Net Revenue Falls
Delek US Q4 Adjusted Net Loss Widens, Net Revenue Falls
Feb 25, 2025
08:08 AM EST, 02/25/2025 (MT Newswires) -- Delek US ( DK ) reported Tuesday that its Q4 adjusted net loss widened to $2.54 per diluted share, from a loss of $1.46 a year earlier. Analysts polled by FactSet expected a loss of $2.82. Net revenue for the quarter ended Dec. 31 was $2.37 billion, compared with $3.94 billion a year...
Copyright 2023-2026 - www.financetom.com All Rights Reserved